An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Ambrx Biopharma Inc. (NYSE: AMAM) announced it will release its full year 2021 financial results on April 26, 2022, after market close. A conference call for discussion of these results will follow at 4:30 p.m. ET. The company focuses on developing Engineered Precision Biologics through an expanded genetic code platform, with candidates targeting various therapeutic areas, including oncology. Investors can access the call via phone or through a webcast.
Positive
Scheduled release of full year 2021 financial results indicates transparency and ongoing investor communication.
Negative
None.
- Conference Call Scheduled for Tuesday, April 26, 2022 at 4:30 p.m. ET -
SAN DIEGO--(BUSINESS WIRE)--
Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics, today announced that the company will release full year 2021 financial results on Tuesday April 26, 2022 after the close of market. Ambrx will host a corresponding conference call and a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on the same day to discuss the results and provide a corporate update.
Individuals interested in listening to the conference call may do so by dialing (844) 200-6205 for domestic callers, or (929) 526-1599 for international callers and reference access code: 9264119; or from the webcast link in the investor relations section of the company's website at: www.ambrx.com.
A webcast replay of the call will be available beginning April 26, 2022 at 4:30 p.m. PT / 7:30 p.m. ET. The webcast will be available in the investor relations section on the company's website for 90 days following the completion of the call.
About Ambrx Biopharma Inc. (Ambrx)
Ambrx is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop Engineered Precision Biologics. These include next generation antibody drug conjugates (ADCs), bispecifics, targeted immuno-oncology therapies, novel cytokines to modulate the immune system, and long-acting therapeutic peptides for metabolic and cardiovascular disease. Ambrx is advancing a robust portfolio of clinical and preclinical programs designed to optimize efficacy, safety and ease of use, in multiple therapeutic areas, including its lead product candidate ARX788. In addition, Ambrx has clinical collaborations with multiple partners, for drug candidates generated using Ambrx technology. For more information, please visit www.ambrx.com.
What date does Ambrx Biopharma plan to release its 2021 financial results?
Ambrx Biopharma plans to release its 2021 financial results on April 26, 2022.
What time is Ambrx's conference call regarding its financial results?
The conference call is scheduled for 4:30 p.m. ET on April 26, 2022.
How can I listen to Ambrx's conference call?
You can listen to Ambrx's conference call by dialing (844) 200-6205 for domestic callers, or (929) 526-1599 for international callers, and referencing access code 9264119, or through a webcast on their website.
What is the focus of Ambrx Biopharma's research and development?
Ambrx Biopharma focuses on Engineered Precision Biologics, including antibody drug conjugates, bispecifics, and targeted immuno-oncology therapies.
